Flagship Pioneering, LLC
CAMBRIDGE, MA · CIK 1400240 · 13F filing filed 2022-08-15
Exempt reporting adviser since 2012 · limited liability company
- Private funds29 · $13.4bn gross assets
- Websiteflagshipventures.com
- Form ADV · 2026-03-31SEC adviser record
- Kindventure
- Others nearbyCambridge, MA
As an employer
- Offices in1 country
- Private fundsventure capital 29
$2.7bn
reported value
-37.7% vs Q1 2022
12positions
99.6%in top 10
0 new
1 added
1 reduced
1 sold out
vs Q1 2022
This report includes the holdings of 7 other managers that share the investment decisions:
- Afeyan Noubar – reports through this filing
- Flagship Pioneering Fund VI General Partner LLC – reports through this filing
- Flagship Pioneering Special Opportunities Fund II General Partner LLC – reports through this filing
- Flagship Ventures Fund IV General Partner LLC – reports through this filing
- Flagship Ventures Fund V General Partner LLC – reports through this filing
- Flagship Ventures Opportunities Fund I General Partner LLC – reports through this filing
- Nutritional Health LTP Fund General Partner LLC – reports through this filing
Shares in two reports are counted once in each security's totals.
Holdings, Q2 2022
The small lines show how much was held over the last 4 quarters (adjusted for stock splits).
| Security | Value | Change |
|---|---|---|
| MODERNA INC MRNA | $1.8bn69.35% | Reduced -4.7m |
| SANA BIOTECHNOLOGY INC SANA | $220.2m8.29% | Unchanged |
| FOGHORN THERAPEUTICS INC FHTX | $172.4m6.49% | Unchanged |
| EVELO BIOSCIENCES INC COM | $106.4m4.01% | Added +27.4m |
| OMEGA THERAPEUTICS INC COMMON STOCK | $98.4m3.71% | Unchanged |
| DENALI THERAPEUTICS INC DNLI | $77.1m2.90% | Unchanged |
| SERES THERAPEUTICS INC COM | $49.3m1.86% | Unchanged |
| AXCELLA HEALTH INC COM | $38.3m1.44% | Unchanged |
| RUBIUS THERAPEUTICS INC RUBY | $32.7m1.23% | Unchanged |
| SIGILON THERAPEUTICS INC COM | $8.6m0.32% | Unchanged |
| CODIAK BIOSCIENCES INC CDAK | $7.5m0.28% | Unchanged |
| SYROS PHARMACEUTICALS INC SYRS | $2.8m0.11% | Unchanged |
Sold out since Q1 2022
| Security | Value then |
|---|---|
| KALEIDO BIOSCIENCES INC KLDO | $32.3m19.6m shares |
Stakes above 5%
Companies where this manager has reported owning more than 5% of a class of shares, on Schedule 13D (may seek influence) or 13G (passive): its latest filing for each, from 19 Dec 2024 on.
| Company | Stake |
|---|---|
| GENERATE BIOMEDICINES INC GENB · 13G · filed 2026-05-15 | 48.9%≈ $1.1bn |